ArticleBiomaterials research2026
Bone Induction as a Function of Size and Chemical Composition of Calcium Phosphate Granules in Osteogrow-C Evaluated in Animal Models: A 1-Year Follow-Up.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Calcium phosphate (CaP) ceramics are widely used in bone regenerative medicine for their osteoconductive properties. Osteogrow-C is a novel device that comprises recombinant human bone morphogenetic protein 6 (rhBMP6) in autologous blood coagulum, utilizing ceramics as a compression-resistant matrix. This study evaluated how CaP granule size and composition affect bone formation and implant integrity in 2 relevant animal models: the rat subcutaneous model and rabbit posterolateral lumbar fusion (PLF) model, over 1 year. The implants in the rat model had varying granule size ranges (74 to 420 μm, 500 to 1,700 μm, 2,360 to 4,000 μm) and compositions [β-tricalcium phosphate (β-TCP), hydroxyapatite (HA), and biphasic ceramics (TCP/HA 80/20)]. Micro-computed tomography (CT) and histology showed that Osteogrow-C induced bone formation on all ceramic scaffolds, with smaller granules resulting in higher bone volume and density, regardless of composition. TCP granules were most resorbed, but residual ceramics persisted in all groups. Based on these findings, Osteogrow-C, containing small granules with different compositions (TCP, HA, TCP/HA 80/20, and TCP/HA 40/60), was further tested in the clinically relevant rabbit PLF model and induced fusion of transverse processes. Importantly, ceramics were more resorbed in the rabbit PLF model, with TCP and TCP/HA 80/20 ceramics showing the highest resorption rate, while HA remained intact. Osteogrow-C containing HA showed increased bone volume; however, biomechanical strength and thicker cortical bone were achieved with TCP and biphasic calcium phosphate (BCP). Finally, in the rat model, bone volume was primarily dependent on granule size, with smaller granules promoting greater bone formation and density. Conversely, in the PLF model, the composition played a more important role-affecting ceramic resorption, bone volume, and biomechanical properties.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.